PMID- 15850317
OWN - NLM
STAT- MEDLINE
DCOM- 20050609
LR  - 20141120
IS  - 0033-2240 (Print)
IS  - 0033-2240 (Linking)
VI  - 61
IP  - 12
DP  - 2004
TI  - [Safety and efficacy of dalteparin administration for elective percutaneous 
      interventions in patients pre-treated with aspirin and ticlopidine].
PG  - 1301-4
AB  - BACKGROUND: Prospective, randomized, double-blind study (POLENOX) proved that 
      administration of low molecular weight heparin (LMWH)--enoxaparin for elective 
      percutaneous coronary interventions (PCI) is as safe and as effective like 
      unfractionated heparin (UFH). The aim of the present study was to determine 
      safety and efficacy of the other LMWH--dalteparin for elective PCI. METHODS: 100 
      patients planned for elective PCI were enrolled to the study. PCI were performed 
      after i.v. dalteparin administration; 120 U/kg (up to 10 000 U). Importantly, all 
      patients were pretreated with aspirin (75-325 mg per day) and ticlopidine (250 mg 
      bid) prior to the procedure. During hospitalization rate of ischemic cardiac 
      events and haemorrhagic complications were assessed. Serial CK and CK-MB were 
      obtained 0, 8, 16, 24 hours after PCI. The results were compared with data from 
      POLENOX study. Group 1 was treated with dalteparin, group 2 with UFH and group 3 
      with enoxaparin. RESULTS: Rate of death, myocardial infarction (CK-MB elevation > 
      x 5 normal level) and repeated revascularization in groups was similar. In group 
      1 (0%; 2%; 1%) in group 2 (0.5%; 2%; 0%) in group 3 (0%, 2%, 0%) respectively. In 
      group 1 CPK elevation (> 3 x normal) after PCI was more frequent (9%) in 
      comparison with group 2 (3.5%) and group 3 (5%), but without statistical 
      significance (p=0.14). Major bleeding complications were not observed in treated 
      groups. Minor bleeding complications were more frequent in group 1 (9%) and 3 
      (8.5%) than in group 2 (2%), p< 0.001. CONCLUSIONS: The use of dalteparin during 
      PCI in patients with aspirin and ticlopidine pre-treatment is safe. However, more 
      frequent benign local bleeding complications and mild CK-MB elevations may be 
      expected.
FAU - Dudek, Dariusz
AU  - Dudek D
AD  - II Klinika Kardiologii Instytutu Kardiologii, Collegium Medium, Uniwersytetu 
      Jagiellonskiego w Krakowie.
FAU - Chyrchel, Michal
AU  - Chyrchel M
FAU - Legutko, Jacek
AU  - Legutko J
FAU - Bartus, Stanislaw
AU  - Bartus S
FAU - Rzeszutko, Lukasz
AU  - Rzeszutko L
FAU - Dubiel, Jacek S
AU  - Dubiel JS
LA  - pol
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Ocena skutecznosci i bezpieczenstwa stosowania dalteparyny podczas przezskornych 
      zabiegow wiencowych (PCI) u pacjentow uprzednio leczonych aspiryna oraz 
      tiklopidyna.
PL  - Poland
TA  - Przegl Lek
JT  - Przeglad lekarski
JID - 19840720R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Fibrinolytic Agents)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
RN  - S79O08V79F (Dalteparin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Angioplasty, Balloon/*methods
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Dalteparin/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Elective Surgical Procedures
MH  - Female
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/etiology/mortality
MH  - Myocardial Ischemia/complications/*drug therapy/*surgery
MH  - Preoperative Care
MH  - Prospective Studies
MH  - Survival Rate
MH  - Ticlopidine/*therapeutic use
EDAT- 2005/04/27 09:00
MHDA- 2005/06/10 09:00
CRDT- 2005/04/27 09:00
PHST- 2005/04/27 09:00 [pubmed]
PHST- 2005/06/10 09:00 [medline]
PHST- 2005/04/27 09:00 [entrez]
PST - ppublish
SO  - Przegl Lek. 2004;61(12):1301-4.